Literature DB >> 21343445

In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.

Pamela McGhee1, Catherine Clark, Kim Credito, Linda Beachel, Glenn A Pankuch, Peter C Appelbaum, Klaudia Kosowska-Shick.   

Abstract

We tested the MICs of fusidic acid (CEM-102) plus other agents against 40 methicillin-resistant Staphylococcus aureus (MRSA) isolates from cystic fibrosis patients and the activities of fusidic acid with or without tobramycin or amikacin against Pseudomonas aeruginosa, MRSA, and Burkholderia cepacia isolates from cystic fibrosis patients in a 24-h time-kill study. Fusidic acid was potent (MICs, 0.125 to 0.5 μg/ml; a single 500-mg dose of fusidic acid at 8 h averaged 8 to 12. 5 μg/ml with 91 to 97% protein binding) against all MRSA strains. No antagonism was observed; synergy occurred for one MRSA strain treated with fusidic acid plus tobramycin.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21343445      PMCID： PMC3088183          DOI： 10.1128/AAC.01672-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Authors:  Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

Review 2.  Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.

Authors:  Benjamin P Howden; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2005-12-15       Impact factor: 9.079

3.  Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Pamela McGhee; Bonifacio Dewasse; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Clinical experiences with fusidic acid in cystic fibrosis patients.

Authors:  T Jensen; S Lanng; M Faber; V T Rosdahl; N Høiby; C Koch
Journal:  J Antimicrob Chemother       Date:  1990-02       Impact factor: 5.790

Review 5.  Update on treatment of pulmonary exacerbations in cystic fibrosis.

Authors:  Alan Smyth
Journal:  Curr Opin Pulm Med       Date:  2006-11       Impact factor: 3.155

6.  Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008.

Authors:  Mariana Castanheira; Amy A Watters; Jan M Bell; John D Turnidge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

7.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

Authors:  Elliott C Dasenbrook; William Checkley; Christian A Merlo; Michael W Konstan; Noah Lechtzin; Michael P Boyle
Journal:  JAMA       Date:  2010-06-16       Impact factor: 56.272

8.  Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol.

Authors:  A Solís; D Brown; J Hughes; H K F Van Saene; D P Heaf
Journal:  Pediatr Pulmonol       Date:  2003-09

9.  Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.

Authors:  L A Garske; T J Kidd; R Gan; J P Bunting; C A Franks; C Coulter; P J Masel; S C Bell
Journal:  J Hosp Infect       Date:  2004-03       Impact factor: 3.926

10.  Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients.

Authors:  L Spicuzza; C Sciuto; G Vitaliti; G Di Dio; S Leonardi; M La Rosa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-29       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.